One patient developing detectable BCL2 G101V and D1013Y mutations on venetoclax and receiving subsequent ibrutinib therapy died from reasons unrelated to CLL during the follow-up period. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.